MOTIVATION FOR: PROMPT APPROVAL OF TRASTUZUMAB BIOSIMILARS TO PROMOTE COMPETITION IN THE MARKET

17 July 2019: Cancer Alliance submits a motivation to SAHPRA for the prompt approval of trastuzumab biosimilars to promote competition in the market.

The Cancer Alliance of South Africa submits this memorandum in support of its request that SAHPRA promptly register biosimilars of the breast cancer medicine trastuzumab
for which manufacturers have submitted New Medicine Launch Forms. We commend SAHPRA for recently approving Mylan’s biosimilar and stress the importance of swiftly
approving the four remaining applications submitted by other trastuzumab biosimilar manufacturers.

Read the full report:


Cancer Alliance , Trastuzumab Motivation for SAHPRA

Related Articles

Related

CELGENE FLAGGED

For overpricing bone marrow cancer drug The Competition Commission has referred for prosecution to the Competition Tribunal (“Tribunal”), international drug manufacturer Celgene Corporation (“Celgene Corp”) and its subsidiary Celgene Logistics S.a.r.l (“Celgene...

read more

Cancer Alliance tackles price gouging

Represented by SECTION27, takes on multinational company Cancer Alliance tackles price gouging 14 November 2024, Johannesburg - The Cancer Alliance, represented by SECTION27, has been admitted by the Competition Tribunal as an intervening party in the excessive...

read more